Dr. Frank Stephen Hodi Jr., MD

Dr. Hodi practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Hodi's NPI, 1730156324, was assigned on March 2, 2006. Dr. Hodi graduated from JS Weill Medical College, Cornell University in 1992. Dr. Hodi holds Massachusetts license 80787.

Dr. Hodi's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Hodi's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Hodi is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Hodi to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hodi practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Hodi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hodi is licensed in Massachusetts.

CMS data shows 165 Medicare services from Dr. Hodi across 1 procedure code in 2024, all of them office visits, for 78 Medicare patients. Medicare paid $12,726 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 78 Medicare patients who saw Dr. Hodi in 2024. The largest group is 65 to 74, with 38 patients. 75% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hodi's median patient age at 72, with 39% women.

In 2022, Dr. Hodi wrote 11 Medicare Part D claims. They cover 1 drug, with $143,631 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Hodi for performance year 2024, reported as part of a group. Dr. Hodi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hodi as offering telehealth.

Dmand AI links 178 papers to Dr. Hodi, published from 2016 to 2025. 2017 was the busiest year, with 20. The most frequent topics are Melanoma, Immunotherapy and Immune Checkpoint Inhibitors. Dr. Hodi has published most often in Clin Cancer Res. Dr. Hodi's most frequent co-authors are Patrick Alexander Ott, MD, Jedd D. Wolchok, MD and Elizabeth I. Buchbinder, MD.

Dmand AI links Dr. Hodi to 2 clinical trials. Conditions studied include Melanoma and Nevi and Melanomas. Bristol-Myers Squibb sponsors the most, 2. Open Payments lists research payments to Dr. Hodi that name 2 trials.

CMS Open Payments shows 337 general payments to Dr. Hodi from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Merck Sharp & Dohme Corporation paid the most, $63,312. It also lists 8 research payments totaling $9,320 from 2016 to 2024, naming 2 clinical trials.

Dr. Hodi graduated from JS Weill Medical College, Cornell University in 1992.